Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aclasta for antiepileptic drug-associated osteoporosis
ACTRN12611000507987Phase 4Not yet recruiting
- Sponsor
- Melbourne Health
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in osteoporosis comparing Aclasta arm with Placebo arm (2 arms). Primary endpoints: Bone mineral density change at 1 year and Exploratory imaging bone assessments. Planned start May 2011; status: not yet recruiting.
02
Drugs
zoledronic acid
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12611000507987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000507987.